Valneva SE

VLA

Company Profile

  • Business description

    Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

  • Contact

    6 Rue Alain Bombard
    Saint-Herblain44800
    FRA

    T: +33 228073710

    E: [email protected]

    https://www.valneva.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    713

Stocks News & Analysis

stocks

Impact of ANZ’s huge fine

Working to prevent repeated failures could also improve competitiveness.
stocks

Acquisition a sign of weakness for overvalued ASX share

Acquisition unlikely to improve prospects in the US and detracts from other opportunities.
stocks

ASX opportunities after earnings season

Finding value in an expensive market.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,120.9034.100.38%
CAC 407,896.9371.690.92%
DAX 4023,748.8650.710.21%
Dow JONES (US)45,883.4549.230.11%
FTSE 1009,277.036.26-0.07%
HKSE26,446.5658.400.22%
NASDAQ22,348.75207.640.94%
Nikkei 22544,768.12395.620.89%
NZX 50 Index13,208.3119.59-0.15%
S&P 5006,615.2830.990.47%
S&P/ASX 2008,853.0031.600.36%
SSE Composite Index3,860.5010.09-0.26%

Market Movers